Study summary · research use only
Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review discusses afamelanotide for erythropoietic protoporphyria (EPP), an inherited disorder of heme biosynthesis in which protoporphyrin IX accumulation causes acute phototoxicity and burning pain after light exposure. The authors summarize afamelanotide's chemical properties, pharmacokinetics, and preclinical and clinical data, describing it as an α-melanocyte-stimulating hormone analog approved for EPP that can activate eumelanogenesis without UV exposure. Clinical studies in EPP are described as showing increased sunlight exposure tolerance and quality-of-life scores with afamelanotide treatment. The authors note the 60-day interval was not based on effectiveness studies and suggest four implants per year at that interval may be insufficient for some patients, and describe common adverse events as headache, fatigue, and nausea.
Abstract
Introduction: In erythropoietic protoporphyria (EPP), an inherited disorder of heme biosynthesis, accumulation of protoporphyrin IX results in acute phototoxicity. EPP patients experience severe burning pain after light exposure, which results in a markedly reduced quality of life. Afamelanotide is the first effective approved medical treatment for EPP, acting on melanocortin-1 receptors. This article aims to review afamelanotide.Areas covered: This review summarizes the chemical properties, pharmacokinetics, safety, preclinical and clinical data on afamelanotide in EPP, and post-marketing surveillance. PubMed search, manufacturers' websites, and relevant articles used for approval by authorities were used for the literature search.Expert opinion: Afamelanotide is an α-melanocyte-stimulating hormone analog. It can activate eumelanogenesis without exposure to UV radiation. Clinical studies in EPP showed that afamelanotide treatment significantly increased exposure to sunlight and QoL. In our clinical experience afamelanotide treatment is much more effective in clinical practice than demonstrated in clinical trials and should be made available for all EPP patients meeting inclusion criteria. The 60-day interval period was not based on effectiveness studies, and therefore for some of the patients the maximum of four implants per year with the 60-day interval is insufficient. Afamelanotide is well tolerated; common adverse events were headache, fatigue, and nausea.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.